Teva Asks FDA To Relist Risperdal Patent And Restore 180-Day Exclusivity

J&J's delisted Risperdal patent should be returned to the "Orange Book" and 180-day exclusivity restored to Teva Pharmaceuticals, the generic company states in a petition to FDA